Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT0GVCH)

• DTT Name: Interleukin-13 (IL13)
• Synonyms: NC30; IL-13
• Gene Name: IL13
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Cytokine: interleukin
• UniProt ID: IL13_HUMAN
• TTD ID: T29143
• Sequence:
  MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAP
  LCNGSMVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRD
  TKIEVAQFVKDLLLHLKKLFREGRFN
• Function: Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses. Positively regulates IL31RA expression in macrophages. Cytokine.
• KEGG Pathway:
  Cytokine-cytokine receptor interaction (hsa04060)
  Jak-STAT signaling pathway (hsa04630)
  Fc epsilon RI signaling pathway (hsa04664)
  Measles (hsa05162)
  Asthma (hsa05310)
  Inflammatory bowel disease (IBD) (hsa05321)
• Reactome Pathway:
  Interleukin-18 signaling (R-HSA-9012546)
  Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807)

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tralokinumab	DM6ENSJ	Atopic dermatitis	EA80	Approved	[2]

13 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cendakimab	DM9LSBJ	Eosinophilic esophagitis	DA24.1	Phase 3	[3]
Dexpramipexole	DM6KXAU	Eosinophilic asthma	CB02.0	Phase 3	[4]
Lebrikizumab	DMQP0X5	Severe asthma	CA23	Phase 3	[1]
Anrukinzumab	DMTG2O0	Asthma	CA23	Phase 2	[5]
Dectrekumab	DM1H7UK	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[6]
PEGylated pitrakinra	DMBPJ9U	Asthma	CA23	Phase 2	[1]
QAX-576	DMUWFI7	Allergic rhinitis	CA08.0	Phase 2	[6]
Romilkimab	DMYEZ5J	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[7]
SAR-156597	DMUICJD	Idiopathic pulmonary fibrosis	CB03.4	Phase 2	[8]
CNTO-5825	DMF8WAT	Allergic asthma	CA23.0	Phase 1	[9]
PF-07264660	DM0GI2H	Atopic dermatitis	EA80	Phase 1	[10]
PF-07275315	DMHRVUY	Atopic dermatitis	EA80	Phase 1	[10]
SAR443765	DMLYI4Z	Asthma	CA23	Phase 1	[11]

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO7040547	DMP0YNU	Asthma	CA23	Discontinued in Phase 1	[12]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Asthma	CA23	Nasal and bronchial airway	5.88E-01	-0.04	-0.1

References

• [1] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan;130(1):21-27.
• [4] Therapeutic strategies for eosinophilic dermatoses. Curr Opin Pharmacol. 2019 Jun;46:29-33.
• [5] Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study.Gut.2015 Jun;64(6):894-900.
• [6] Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol. 2015 Feb;135(2):500-7.
• [7] A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2020 Dec;79(12):1600-1607.
• [8] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [9] Safety, tolerability and pharmacokinetics of a human anti-interleukin-13 monoclonal antibody (CNTO 5825) in an ascending single-dose first-in-human study. Br J Clin Pharmacol. 2013 May;75(5):1289-98.
• [10] Clinical pipeline report, company report or official report of Pfizer
• [11] Clinical pipeline report, company report or official report of Sanofi
• [12] Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.